In:
Interventional Cardiology Review, Radcliffe Media Media Ltd, Vol. 4, No. 1 ( 2009), p. 34-
Abstract:
Seven years after the first-in-man transcatheter aortic valve implantation (TAVI) for the treatment of aortic stenosis, it remains a dynamic field of research and development. Evidence from 8,000 patients treated worldwide suggests that TAVI is feasible and provides haemodynamic and clinical improvement for up to three years in patients at high risk or with contraindications to surgery. Pending questions mainly concern safety and long-term durability. Today these techniques are targeted at high-risk patients, but they may be extended to lower-risk groups in the future if their initial promise holds true after careful evaluation.
Type of Medium:
Online Resource
ISSN:
1756-1477
DOI:
10.15420/icr.2009.4.1.34
Language:
English
Publisher:
Radcliffe Media Media Ltd
Publication Date:
2009
detail.hit.zdb_id:
2813989-6
Permalink